Hsp104 Suppresses Polyglutamine-Induced Degeneration Post Onset in a Drosophila MJD/SCA3 Model

English version České info

There are no effective therapeutics that antagonize or reverse the protein-misfolding events underpinning polyglutamine (PolyQ) disorders, including Spinocerebellar Ataxia Type-3 (SCA3). Here, we augment the proteostasis network of Drosophila SCA3 models with Hsp104, a powerful protein disaggregase from yeast, which is bafflingly absent from metazoa. Hsp104 suppressed eye degeneration caused by a C-terminal ataxin-3 (MJD) fragment containing the pathogenic expanded PolyQ tract, but unexpectedly enhanced aggregation and toxicity of full-length pathogenic MJD. Hsp104 suppressed toxicity of MJD variants lacking a portion of the N-terminal deubiquitylase domain and full-length MJD variants unable to engage polyubiquitin, indicating that MJD-ubiquitin interactions hinder protective Hsp104 modalities. Importantly, in staging experiments, Hsp104 suppressed toxicity of a C-terminal MJD fragment when expressed after the onset of PolyQ-induced degeneration, whereas Hsp70 was ineffective. Thus, we establish the first disaggregase or chaperone treatment administered after the onset of pathogenic protein-induced degeneration that mitigates disease progression.

Vyšlo v časopise: Hsp104 Suppresses Polyglutamine-Induced Degeneration Post Onset in a Drosophila MJD/SCA3 Model. PLoS Genet 9(9): e32767. doi:10.1371/journal.pgen.1003781
Kategorie: Research Article
prolekare.web.journal.doi_sk: https://doi.org/10.1371/journal.pgen.1003781

Souhrn

Zdroje

1. FormanMS, TrojanowskiJQ, LeeVM (2004) Neurodegenerative diseases: a decade of discoveries paves the way for therapeutic breakthroughs. Nat Med 10 : 1055–1063.

2. ChitiF, DobsonCM (2006) Protein misfolding, functional amyloid, and human disease. Annu Rev Biochem 75 : 333–366.

3. CushmanM, JohnsonBS, KingOD, GitlerAD, ShorterJ (2010) Prion-like disorders: blurring the divide between transmissibility and infectivity. J Cell Sci 123 : 1191–1201.

4. WestermarkP, BensonMD, BuxbaumJN, CohenAS, FrangioneB, et al. (2005) Amyloid: toward terminology clarification. Report from the Nomenclature Committee of the International Society of Amyloidosis. Amyloid 12 : 1–4.

5. DeSantisME, LeungEH, SweenyEA, JackrelME, Cushman-NickM, et al. (2012) Operational plasticity enables hsp104 to disaggregate diverse amyloid and nonamyloid clients. Cell 151 : 778–793.

6. TessarzP, MogkA, BukauB (2008) Substrate threading through the central pore of the Hsp104 chaperone as a common mechanism for protein disaggregation and prion propagation. Mol Microbiol 68 : 87–97.

7. WendlerP, ShorterJ, PlissonC, CashikarAG, LindquistS, et al. (2007) Atypical AAA+ subunit packing creates an expanded cavity for disaggregation by the protein-remodeling factor Hsp104. Cell 131 : 1366–1377.

8. WendlerP, ShorterJ, SneadD, PlissonC, ClareDK, et al. (2009) Motor mechanism for protein threading through Hsp104. Mol Cell 34 : 81–92.

9. SanchezY, LindquistSL (1990) HSP104 required for induced thermotolerance. Science 248 : 1112–1115.

10. ParsellDA, KowalAS, SingerMA, LindquistS (1994) Protein disaggregation mediated by heat-shock protein Hsp104. Nature 372 : 475–478.

11. AlbertiS, HalfmannR, KingO, KapilaA, LindquistS (2009) A systematic survey identifies prions and illuminates sequence features of prionogenic proteins. Cell 137 : 146–158.

12. ShorterJ, LindquistS (2004) Hsp104 catalyzes formation and elimination of self-replicating Sup35 prion conformers. Science 304 : 1793–1797.

13. ShorterJ, LindquistS (2006) Destruction or potentiation of different prions catalyzed by similar Hsp104 remodeling activities. Mol Cell 23 : 425–438.

14. RampeltH, Kirstein-MilesJ, NillegodaNB, ChiK, ScholzSR, et al. (2012) Metazoan Hsp70 machines use Hsp110 to power protein disaggregation. EMBO J 31 : 4221–4235.

15. ShorterJ (2011) The mammalian disaggregase machinery: Hsp110 synergizes with Hsp70 and Hsp40 to catalyze protein disaggregation and reactivation in a cell-free system. PLoS One 6: e26319.

16. DuennwaldML, EcheverriaA, ShorterJ (2012) Small heat shock proteins potentiate amyloid dissolution by protein disaggregases from yeast and humans. PLoS Biol 10: e1001346.

17. VashistS, CushmanM, ShorterJ (2010) Applying Hsp104 to protein-misfolding disorders. Biochem Cell Biol 88 : 1–13.

18. ShorterJ (2008) Hsp104: a weapon to combat diverse neurodegenerative disorders. Neurosignals 16 : 63–74.

19. BettencourtC, LimaM (2011) Machado-Joseph Disease: from first descriptions to new perspectives. Orphanet J Rare Dis 6 : 35.

20. PaulsonH (2012) Machado-Joseph disease/spinocerebellar ataxia type 3. Handb Clin Neurol 103 : 437–449.

21. PaulsonHL, DasSS, CrinoPB, PerezMK, PatelSC, et al. (1997) Machado-Joseph disease gene product is a cytoplasmic protein widely expressed in brain. Ann Neurol 41 : 453–462.

22. PaulsonHL, PerezMK, TrottierY, TrojanowskiJQ, SubramonySH, et al. (1997) Intranuclear inclusions of expanded polyglutamine protein in spinocerebellar ataxia type 3. Neuron 19 : 333–344.

23. TakiyamaY, NishizawaM, TanakaH, KawashimaS, SakamotoH, et al. (1993) The gene for Machado-Joseph disease maps to human chromosome 14q. Nat Genet 4 : 300–304.

24. WinbornBJ, TravisSM, TodiSV, ScaglioneKM, XuP, et al. (2008) The deubiquitinating enzyme ataxin-3, a polyglutamine disease protein, edits Lys63 linkages in mixed linkage ubiquitin chains. J Biol Chem 283 : 26436–26443.

25. KuhlbrodtK, JanieschPC, KeveiE, SegrefA, BarikbinR, et al. (2011) The Machado-Joseph disease deubiquitylase ATX-3 couples longevity and proteostasis. Nat Cell Biol 13 : 273–281.

26. MasinoL, MusiV, MenonRP, FusiP, KellyG, et al. (2003) Domain architecture of the polyglutamine protein ataxin-3: a globular domain followed by a flexible tail. FEBS Lett 549 : 21–25.

27. EllisdonAM, PearceMC, BottomleySP (2007) Mechanisms of ataxin-3 misfolding and fibril formation: kinetic analysis of a disease-associated polyglutamine protein. J Mol Biol 368 : 595–605.

28. EllisdonAM, ThomasB, BottomleySP (2006) The two-stage pathway of ataxin-3 fibrillogenesis involves a polyglutamine-independent step. J Biol Chem 281 : 16888–16896.

29. MasinoL, NicastroG, MenonRP, Dal PiazF, CalderL, et al. (2004) Characterization of the structure and the amyloidogenic properties of the Josephin domain of the polyglutamine-containing protein ataxin-3. J Mol Biol 344 : 1021–1035.

30. ShorterJ, LindquistS (2008) Hsp104, Hsp70 and Hsp40 interplay regulates formation, growth and elimination of Sup35 prions. EMBO J 27 : 2712–2724.

31. Lo BiancoC, ShorterJ, RegulierE, LashuelH, IwatsuboT, et al. (2008) Hsp104 antagonizes alpha-synuclein aggregation and reduces dopaminergic degeneration in a rat model of Parkinson disease. J Clin Invest 118 : 3087–3097.

32. PerrinV, RegulierE, Abbas-TerkiT, HassigR, BrouilletE, et al. (2007) Neuroprotection by Hsp104 and Hsp27 in lentiviral-based rat models of Huntington's disease. Mol Ther 15 : 903–911.

33. SatyalSH, SchmidtE, KitagawaK, SondheimerN, LindquistS, et al. (2000) Polyglutamine aggregates alter protein folding homeostasis in Caenorhabditis elegans. Proc Natl Acad Sci U S A 97 : 5750–5755.

34. VacherC, Garcia-OrozL, RubinszteinDC (2005) Overexpression of yeast hsp104 reduces polyglutamine aggregation and prolongs survival of a transgenic mouse model of Huntington's disease. Hum Mol Genet 14 : 3425–3433.

35. Dandoy-DronF, BogdanovaA, BeringueV, BaillyY, ToveyMG, et al. (2006) Infection by ME7 prion is not modified in transgenic mice expressing the yeast chaperone Hsp104 in neurons. Neurosci Lett 405 : 181–185.

36. MosserDD, HoS, GloverJR (2004) Saccharomyces cerevisiae Hsp104 enhances the chaperone capacity of human cells and inhibits heat stress-induced proapoptotic signaling. Biochemistry 43 : 8107–8115.

37. TrinhK, MooreK, WesPD, MuchowskiPJ, DeyJ, et al. (2008) Induction of the phase II detoxification pathway suppresses neuron loss in Drosophila models of Parkinson's disease. J Neurosci 28 : 465–472.

38. BrandAH, PerrimonN (1993) Targeted gene expression as a means of altering cell fates and generating dominant phenotypes. Development 118 : 401–415.

39. RitsonGP, CusterSK, FreibaumBD, GuintoJB, GeffelD, et al. (2010) TDP-43 mediates degeneration in a novel Drosophila model of disease caused by mutations in VCP/p97. J Neurosci 30 : 7729–7739.

40. WarrickJM, PaulsonHL, Gray-BoardGL, BuiQT, FischbeckKH, et al. (1998) Expanded polyglutamine protein forms nuclear inclusions and causes neural degeneration in Drosophila. Cell 93 : 939–949.

41. WarrickJM, MorabitoLM, BilenJ, Gordesky-GoldB, FaustLZ, et al. (2005) Ataxin-3 suppresses polyglutamine neurodegeneration in Drosophila by a ubiquitin-associated mechanism. Mol Cell 18 : 37–48.

42. HaackeA, HartlFU, BreuerP (2007) Calpain inhibition is sufficient to suppress aggregation of polyglutamine-expanded ataxin-3. J Biol Chem 282 : 18851–18856.

43. JungJ, XuK, LessingD, BoniniNM (2009) Preventing Ataxin-3 protein cleavage mitigates degeneration in a Drosophila model of SCA3. Hum Mol Genet 18 : 4843–4852.

44. CummingsCJ, ManciniMA, AntalffyB, DeFrancoDB, OrrHT, et al. (1998) Chaperone suppression of aggregation and altered subcellular proteasome localization imply protein misfolding in SCA1. Nat Genet 19 : 148–154.

45. WarrickJM, ChanHY, Gray-BoardGL, ChaiY, PaulsonHL, et al. (1999) Suppression of polyglutamine-mediated neurodegeneration in Drosophila by the molecular chaperone HSP70. Nat Genet 23 : 425–428.

46. ChanHY, WarrickJM, Gray-BoardGL, PaulsonHL, BoniniNM (2000) Mechanisms of chaperone suppression of polyglutamine disease: selectivity, synergy and modulation of protein solubility in Drosophila. Hum Mol Genet 9 : 2811–2820.

47. MuchowskiPJ, SchaffarG, SittlerA, WankerEE, Hayer-HartlMK, et al. (2000) Hsp70 and hsp40 chaperones can inhibit self-assembly of polyglutamine proteins into amyloid-like fibrils. Proc Natl Acad Sci U S A 97 : 7841–7846.

48. HalfmannR, LindquistS (2008) Screening for amyloid aggregation by Semi-Denaturing Detergent-Agarose Gel Electrophoresis. J Vis Exp 17: e838 doi:810.3791/3838

49. SanchezY, ParsellDA, TaulienJ, VogelJL, CraigEA, et al. (1993) Genetic evidence for a functional relationship between Hsp104 and Hsp70. J Bacteriol 175 : 6484–6491.

50. BettencourtC, SantosC, MontielR, Costa MdoC, Cruz-MoralesP, et al. (2010) Increased transcript diversity: novel splicing variants of Machado-Joseph disease gene (ATXN3). Neurogenetics 11 : 193–202.

51. HarrisGM, DodelzonK, GongL, Gonzalez-AlegreP, PaulsonHL (2010) Splice isoforms of the polyglutamine disease protein ataxin-3 exhibit similar enzymatic yet different aggregation properties. PLoS One 5: e13695.

52. DiSalvoS, DerdowskiA, PezzaJA, SerioTR (2011) Dominant prion mutants induce curing through pathways that promote chaperone-mediated disaggregation. Nat Struct Mol Biol 18 : 486–492.

53. RomanG, DavisRL (2002) Conditional expression of UAS-transgenes in the adult eye with a new gene-switch vector system. Genesis 34 : 127–131.

54. OsterwalderT, YoonKS, WhiteBH, KeshishianH (2001) A conditional tissue-specific transgene expression system using inducible GAL4. Proc Natl Acad Sci U S A 98 : 12596–12601.

55. JuS, TardiffDF, HanH, DivyaK, ZhongQ, et al. (2011) A yeast model of FUS/TLS-dependent cytotoxicity. PLoS Biol 9: e1001052.

56. ArmakolaM, HigginsMJ, FigleyMD, BarmadaSJ, ScarboroughEA, et al. (2012) Inhibition of RNA lariat debranching enzyme suppresses TDP-43 toxicity in ALS disease models. Nat Genet 44 : 1302–1309.

57. SunZ, DiazZ, FangX, HartMP, ChesiA, et al. (2011) Molecular determinants and genetic modifiers of aggregation and toxicity for the ALS disease protein FUS/TLS. PLoS Biol 9: e1000614.

58. ShorterJ, LindquistS (2005) Prions as adaptive conduits of memory and inheritance. Nat Rev Genet 6 : 435–450.

59. DeSantisME, ShorterJ (2012) Hsp104 drives “protein-only” positive selection of Sup35 prion strains encoding strong [PSI(+)]. Chem Biol 19 : 1400–1410.

60. Nekooki-MachidaY, KurosawaM, NukinaN, ItoK, OdaT, et al. (2009) Distinct conformations of in vitro and in vivo amyloids of huntingtin-exon1 show different cytotoxicity. Proc Natl Acad Sci U S A 106 : 9679–9684.

61. OlzschaH, SchermannSM, WoernerAC, PinkertS, HechtMH, et al. (2011) Amyloid-like aggregates sequester numerous metastable proteins with essential cellular functions. Cell 144 : 67–78.

62. VabulasRM, HartlFU (2011) Aberrant protein interactions in amyloid disease. Cell Cycle 10 : 1512–1513.

63. DouglasPM, TreuschS, RenHY, HalfmannR, DuennwaldML, et al. (2008) Chaperone-dependent amyloid assembly protects cells from prion toxicity. Proc Natl Acad Sci U S A 105 : 7206–7211.

64. WolfeKJ, CyrDM (2011) Amyloid in neurodegenerative diseases: friend or foe? Semin Cell Dev Biol 22 : 476–481.

65. DobsonCM (2003) Protein folding and misfolding. Nature 426 : 884–890.

66. CarmichaelJ, ChatellierJ, WoolfsonA, MilsteinC, FershtAR, et al. (2000) Bacterial and yeast chaperones reduce both aggregate formation and cell death in mammalian cell models of Huntington's disease. Proc Natl Acad Sci U S A 97 : 9701–9705.

67. WellingtonCL, EllerbyLM, HackamAS, MargolisRL, TrifiroMA, et al. (1998) Caspase cleavage of gene products associated with triplet expansion disorders generates truncated fragments containing the polyglutamine tract. J Biol Chem 273 : 9158–9167.

68. GrahamRK, DengY, SlowEJ, HaighB, BissadaN, et al. (2006) Cleavage at the caspase-6 site is required for neuronal dysfunction and degeneration due to mutant huntingtin. Cell 125 : 1179–1191.

69. DuennwaldML, JagadishS, MuchowskiPJ, LindquistS (2006) Flanking sequences profoundly alter polyglutamine toxicity in yeast. Proc Natl Acad Sci U S A 103 : 11045–11050.

70. MasinoL, NicastroG, De SimoneA, CalderL, MolloyJ, et al. (2011) The Josephin domain determines the morphological and mechanical properties of ataxin-3 fibrils. Biophys J 100 : 2033–2042.

71. NicastroG, MenonRP, MasinoL, KnowlesPP, McDonaldNQ, et al. (2005) The solution structure of the Josephin domain of ataxin-3: structural determinants for molecular recognition. Proc Natl Acad Sci U S A 102 : 10493–10498.

72. MuchowskiPJ, WackerJL (2005) Modulation of neurodegeneration by molecular chaperones. Nat Rev Neurosci 6 : 11–22.

73. BroadleySA, HartlFU (2009) The role of molecular chaperones in human misfolding diseases. FEBS Lett 583 : 2647–2653.

74. ShenHY, HeJC, WangY, HuangQY, ChenJF (2005) Geldanamycin induces heat shock protein 70 and protects against MPTP-induced dopaminergic neurotoxicity in mice. J Biol Chem 280 : 39962–39969.

75. McLeanPJ, KluckenJ, ShinY, HymanBT (2004) Geldanamycin induces Hsp70 and prevents alpha-synuclein aggregation and toxicity in vitro. Biochem Biophys Res Commun 321 : 665–669.

76. AuluckPK, BoniniNM (2002) Pharmacological prevention of Parkinson disease in Drosophila. Nat Med 8 : 1185–1186.

77. WangAM, MiyataY, KlinedinstS, PengHM, ChuaJP, et al. (2012) Activation of Hsp70 reduces neurotoxicity by promoting polyglutamine protein degradation. Nat Chem Biol 9 : 112–8.

78. BraakH, Del TrediciK, RubU, de VosRA, Jansen SteurEN, et al. (2003) Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 24 : 197–211.

79. NaslundJ, HaroutunianV, MohsR, DavisKL, DaviesP, et al. (2000) Correlation between elevated levels of amyloid beta-peptide in the brain and cognitive decline. JAMA 283 : 1571–1577.

80. DaviesSW, TurmaineM, CozensBA, DiFigliaM, SharpAH, et al. (1997) Formation of neuronal intranuclear inclusions underlies the neurological dysfunction in mice transgenic for the HD mutation. Cell 90 : 537–548.

81. BainbridgeJW, SmithAJ, BarkerSS, RobbieS, HendersonR, et al. (2008) Effect of gene therapy on visual function in Leber's congenital amaurosis. N Engl J Med 358 : 2231–2239.

82. Hacein-Bey-AbinaS, Le DeistF, CarlierF, BouneaudC, HueC, et al. (2002) Sustained correction of X-linked severe combined immunodeficiency by ex vivo gene therapy. N Engl J Med 346 : 1185–1193.

83. MaguireAM, SimonelliF, PierceEA, PughENJr, MingozziF, et al. (2008) Safety and efficacy of gene transfer for Leber's congenital amaurosis. N Engl J Med 358 : 2240–2248.

84. FeiginA, KaplittMG, TangC, LinT, MattisP, et al. (2007) Modulation of metabolic brain networks after subthalamic gene therapy for Parkinson's disease. Proc Natl Acad Sci U S A 104 : 19559–19564.

85. KaplittMG, FeiginA, TangC, FitzsimonsHL, MattisP, et al. (2007) Safety and tolerability of gene therapy with an adeno-associated virus (AAV) borne GAD gene for Parkinson's disease: an open label, phase I trial. Lancet 369 : 2097–2105.

86. StoesslAJ (2007) Gene therapy for Parkinson's disease: early data. Lancet 369 : 2056–2058.

87. SimonatoM, BennettJ, BoulisNM, CastroMG, FinkDJ, et al. (2013) Progress in gene therapy for neurological disorders. Nat Rev Neurol 9 : 298.

88. San SebastianW, SamaranchL, KellsAP, ForsayethJ, BankiewiczKS (2013) Gene Therapy for Misfolding Protein Diseases of the Central Nervous System. Neurotherapeutics 10 : 498–510.

89. SchiavoG, BenfenatiF, PoulainB, RossettoO, Polverino de LauretoP, et al. (1992) Tetanus and botulinum-B neurotoxins block neurotransmitter release by proteolytic cleavage of synaptobrevin. Nature 359 : 832–835.

90. YehFL, ZhuY, TeppWH, JohnsonEA, BerticsPJ, et al. (2011) Retargeted clostridial neurotoxins as novel agents for treating chronic diseases. Biochemistry 50 : 10419–10421.

91. HallettM (1999) One man's poison–clinical applications of botulinum toxin. N Engl J Med 341 : 118–120.

92. EsquenaziA, MayerNH, EliaAE, AlbaneseA (2009) Botulinum toxin for the management of adult patients with upper motor neuron syndrome. Toxicon 54 : 634–638.

93. EliaAE, FilippiniG, CalandrellaD, AlbaneseA (2009) Botulinum neurotoxins for post-stroke spasticity in adults: a systematic review. Mov Disord 24 : 801–812.

94. BentivoglioAR, AlbaneseA (1999) Botulinum toxin in motor disorders. Curr Opin Neurol 12 : 447–456.

95. OsborneSL, LathamCF, WenPJ, CavaignacS, FanningJ, et al. (2007) The Janus faces of botulinum neurotoxin: sensational medicine and deadly biological weapon. J Neurosci Res 85 : 1149–1158.

96. HayBA, WolffT, RubinGM (1994) Expression of baculovirus P35 prevents cell death in Drosophila. Development 120 : 2121–2129.

97. ShenJ, CurtisC, TavareS, TowerJ (2009) A screen of apoptosis and senescence regulatory genes for life span effects when over-expressed in Drosophila. Aging (Albany NY) 1 : 191–211.